Latest From PharmaEngine Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Ipsen's new CEO David Meek has conducted the French company's biggest ever deal by acquiring Onivyde for pancreatic cancer from Merrimack Pharmaceuticals, and believes Ipsen will turn Onivyde's fortunes around.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
CEO removed as part of 22% staff cut as Merrimack looks to increase runway while awaiting data to add first-line pancreatic cancer to the Onivyde label.
- Therapeutic Areas
- Infectious & Viral Diseases
- Pacific Rim
- Parent & Subsidiaries
- PharmaEngine Inc.
- Senior Management
C. Grace Yeh, PhD, Pres. & CEO
C.S. Chang, Sr. Dir., Fin. & Admin.
- Contact Info
Phone: (886) 2 2515 8228
16F, 237 Sung-Chiang Rd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.